Anti-tumor poly allylamine nanoparticle-based vaccine platform

BIANCHI, DAIANA; QUEREDA CORSO, MICAELA BELÉN; CHAVERO, CAMILA; SMALDINI, PAOLA

San Luis

Congreso; Reunión Anual de la Sociedad Argentina de Inmunología 2023; 2023

Sociedad Argentina de Inmunología

Nanotechnology has shown promising results for cancer immunotherapy. Nanoparticles trigger the immune response by enhancing antigen presentation on phagocytic cells and activating T cells. Here, we focused on a vaccine PAH nanoparticle platform to control tumor cell growth in a mouse model.C57BL/6 male mice were immunized with two doses of Np-OVA, OVA or PBS at 14 day-interval through intramuscular (IM), subcutaneous (SC) or combined routes (IM+SC). On day 21, mice were subcutaneously injected with the tumor cell line B16-OVA. Tumors were macroscopically monitored and mice were euthanized when tumor volume reached >1500 mm3. Humoral (IgG) and cellular (T cells and NK cells) immune responses were evaluated by ELISA and flow cytometry, respectively. Mice from PBS, OVA and Np-OVA IM groups developed tumors with a mean volume of 737,43mm3, 999,47mm3 and 561,84mm3, respectively. On the other hand, in the Np-OVA SC group, 2 out of 5 mice developed tumors with a mean volume of 154,71mm3 (p